Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00462982
Recruitment Status : Completed
First Posted : April 19, 2007
Results First Posted : December 30, 2015
Last Update Posted : December 30, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma.

Condition or disease Intervention/treatment Phase
Kidney Cancer Melanoma (Skin) Metastatic Cancer Drug: sunitinib malate Phase 2

Detailed Description:



  • Determine the efficacy of sunitinib malate, in terms of objective radiographic response of brain lesions, in patients with brain metastases secondary to renal cell carcinoma or melanoma.


  • Determine overall and progression-free survival.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
Study Start Date : March 2007
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Arm Intervention/treatment
Experimental: Sunitinib
Patients will be treated with 50 mg daily for four out of every six weeks.
Drug: sunitinib malate

Primary Outcome Measures :
  1. Central Nervous System (CNS) Response Rate by RECIST Criteria [ Time Frame: up to a year ]
    Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, X-ray) or as >10 mm with spiral CT scan. This study will use a minimum diameter of 10 mm for measurable lesions in the brain, regardless of imaging modality. All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters). All other lesions are considered non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, and cystic lesions are all nonmeasurable.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed melanoma or renal cell carcinoma

    • Metastatic brain disease
  • Must have assessable target intracranial lesion(s), defined as measurable disease ≥ 10 mm in longest diameter that is not appropriate for stereotactic radiosurgery or surgical resection

    • Lesions previously treated with radiosurgery AND not eligible for resection can only be used as target lesions if there has been true tumor progression on baseline scan (i.e., ≥ 20% increase in longest diameter of lesion) rather than radionecrosis

      • True progression must be confirmed by PET scan or other corroborating imaging used to distinguish radionecrosis
  • No leptomeningeal metastases or primary dural metastases


  • ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Total leukocyte count ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 2.0 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • Hemoglobin ≥ 9.0 g/dL
  • Calcium ≤ 12.0 mg/dL
  • AST and ALT ≤ 1.5 times ULN
  • PT ≤ 1.5 times ULN
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No uncontrolled medical illness including, but not limited to, any of the following:

    • Hypertension (i.e., blood pressure > 150/100 mm Hg)
    • Thyroid disease
    • Severe valvular disease
    • Severe pulmonary disease
    • HIV/AIDS
    • Severe psychiatric illness
  • No cardiac dysrhythmia ≥ grade 2
  • No prolonged QTc interval on baseline EKG
  • No systemic hemorrhage ≥ grade 2 within the past 4 weeks

    • No CNS hemorrhage ≥ grade 2

      • Grade 1 (asymptomatic) CNS hemorrhage allowed at investigator's discretion
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Unstable angina
    • Symptomatic congestive heart failure
    • Stroke/transient ischemic attack
    • Pulmonary embolism
  • Ejection fraction ≥ 50% by baseline echocardiogram OR < 20% decrease in ejection fraction from a prior study


  • No prior multi-targeted tyrosine kinase inhibitor therapy (e.g., sunitinib malate or sorafenib)
  • No coronary/peripheral arterial bypass surgery within the past 6 months
  • More than 4 weeks since prior surgery and recovered
  • More than 4 weeks since prior and no other concurrent experimental therapy or cytotoxic chemotherapy
  • More than 4 weeks since prior immunotherapy
  • More than 2 weeks since prior stereotactic radiosurgery and recovered
  • More than 7 days since prior and no concurrent drugs that interact with CYP3A4 family, including enzyme-inducing antiepileptic drugs, warfarin, or Hypericum perforatum extract (St. John's wort)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00462982

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Lauren E. Abrey, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Paul B. Chapman, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Robert J. Motzer, MD Memorial Sloan Kettering Cancer Center

Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00462982     History of Changes
Other Study ID Numbers: 07-009
P30CA008748 ( U.S. NIH Grant/Contract )
First Posted: April 19, 2007    Key Record Dates
Results First Posted: December 30, 2015
Last Update Posted: December 30, 2015
Last Verified: November 2015

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage IV melanoma
tumors metastatic to brain
stage IV renal cell cancer
recurrent melanoma
recurrent renal cell cancer

Additional relevant MeSH terms:
Neoplasm Metastasis
Kidney Neoplasms
Carcinoma, Renal Cell
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors